Chemotherapy and herceptin for HER-2+ metastatic breast cancer:: The best drug?

被引：7

作者：

Livingston, RB

Esteva, FJ

机构：

[1] Seattle Canc Care Alliance, Dept Med, Seattle, WA 98109 USA

[2] Univ Texas, MD Anderson Canc Ctr, Houston, TX 77030 USA

来源：

ONCOLOGIST | 2001年 / 6卷 / 04期

关键词：

D O I：

10.1634/theoncologist.6-4-315

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

引用

页码：315 / 316

页数：2

共 7 条

[1] Clinical activity of trastuzumab and vinorelbine in women with HER2-overexpressing metastatic breast cancer [J].

Burstein, HJ ;

Kuter, I ;

Campos, SM ;

Gelman, RS ;

Tribou, L ;

Parker, LM ;

Manola, J ;

Younger, J ;

Matulonis, U ;

Bunnell, CA ;

Partridge, AH ;

Richardson, PG ;

Clarke, K ;

Shulman, LN ;

Winer, EP .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) :2722-2730

[2] Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease [J].

Cobleigh, MA ;

Vogel, CL ;

Tripathy, D ;

Robert, NJ ;

Scholl, S ;

Fehrenbacher, L ;

Wolter, JM ;

Paton, V ;

Shak, S ;

Lieberman, G ;

Slamon, DJ .

JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (09) :2639-2648

[3]

OSOBA D, 2001, P AM SOC CLIN ONCOL, V19, pA28

[4] Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs [J].

Pietras, RJ ;

Pegram, MD ;

Finn, RS ;

Maneval, DA ;

Slamon, DJ .

ONCOGENE, 1998, 17 (17) :2235-2249

[5] Weekly trastuzumab and paclitaxel therapy for metastatic breast cancer with analysis of efficacy by HER2 immunophenotype and gene amplification [J].

Seidman, AD ;

Fornier, MN ;

Esteva, FJ ;

Tan, L ;

Kaptain, S ;

Bach, A ;

Panageas, KS ;

Arroyo, C ;

Valero, V ;

Currie, V ;

Gilewski, T ;

Theodoulou, M ;

Moynahan, ME ;

Moasser, M ;

Sklarin, N ;

Dickler, M ;

D'Andrea, G ;

Cristofanilli, M ;

Rivera, E ;

Hortobagyi, GN ;

Norton, L ;

Hudis, CA .

JOURNAL OF CLINICAL ONCOLOGY, 2001, 19 (10) :2587-2595

[6] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].

Slamon, DJ ;

Leyland-Jones, B ;

Shak, S ;

Fuchs, H ;

Paton, V ;

Bajamonde, A ;

Fleming, T ;

Eiermann, W ;

Wolter, J ;

Pegram, M ;

Baselga, J ;

Norton, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792

[7]

VOGEL CL, 1998, BREAST CANC RES TREA, V50, pA232

← 1 →